⌘K (Command K) to search

Sign in Sign up free

Insider · CIK 0001808244

Lazarus Alon

Reports to the SEC for 2 companies · WATERTOWN, MA

Transactions

18

Companies

2

Filings

6

CIK

0001808244

Forms 4 and 5

Insider transactions

18 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-06-12	HOWLWerewolf Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+27K sh	—	—	27,000
2024-05-24	HOWLWerewolf Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+17.5K sh	—	—	17,500
2023-06-21	HOWLWerewolf Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+13.2K sh	—	—	13,200
2022-06-01	HOWLWerewolf Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+11.6K sh	—	—	11,600
2021-05-04	HOWLWerewolf Therapeutics, Inc.C Conversion	Director	CConversion	+1.24M sh	—	—	1,235,917
2021-05-04	HOWLWerewolf Therapeutics, Inc.C Conversion	Director	CConversion	+411K sh	—	—	1,646,634
2021-05-04	HOWLWerewolf Therapeutics, Inc.P Purchase	Director	PPurchase	+400K sh	$16.00	+$6.4M	2,046,634
2021-05-04	HOWLWerewolf Therapeutics, Inc. · Series A Preferred StockC Conversion	Director	CConversion	−10.7M sh	—	—	0
2021-05-04	HOWLWerewolf Therapeutics, Inc. · Series B Preferred StockC Conversion	Director	CConversion	−3.56M sh	—	—	0
2021-04-30	HOWLWerewolf Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+23.2K sh	—	—	23,200
2020-12-23	HOWLWerewolf Therapeutics, Inc. · Series B Preferred StockP Purchase	Director	PPurchase	+3.56M sh	$0.92	+$3.28M	3,560,551
2020-04-13	KROSKeros Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+1.38M sh	—	—	1,382,295
2020-04-13	KROSKeros Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+343K sh	—	—	1,725,565
2020-04-13	KROSKeros Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+168K sh	—	—	1,893,102
2020-04-13	KROSKeros Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+120K sh	$16.00	+$1.92M	2,013,102
2020-04-13	KROSKeros Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.38M sh	—	—	0
2020-04-13	KROSKeros Therapeutics, Inc. · Series B-1 Preferred StockC Conversion	Director, 10% Owner	CConversion	−343K sh	—	—	0
2020-04-13	KROSKeros Therapeutics, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−168K sh	—	—	0

Recent filings

6

Accepted (ET)
Jun 134
Lazarus Alon0000950170-25-086174
SEC(opens sec.gov)
May 244
Lazarus Alon0000950170-24-064829
SEC(opens sec.gov)
Jun 234
Lazarus Alon0000899243-23-016380
SEC(opens sec.gov)
Jun 34
Lazarus Alon0000899243-22-020982
SEC(opens sec.gov)
May 44
Lazarus Alon0000899243-21-018111
SEC(opens sec.gov)
Apr 134
Lazarus Alon0001209191-20-024228
SEC(opens sec.gov)

Companies

2

Address

C/O WEREWOLF THERAPEUTICS, INC. 200 TALCOTT AVENUE, 2ND FLOOR

WATERTOWN, MA, 02472